| abstract |
The present invention relates to a pharmaceutical preparation of abiraterone acetate and ARN-509, which is an androgen receptor (AR) related disease or condition, in particular cancer, more particularly prostate cancer, such as But not castration resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy untreated metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer or high risk non-metastatic castration resistant prostate It can be administered to mammals, particularly humans, suffering from cancer and the like. In one aspect, these formulations comprise solid dispersions of abiraterone acetate and ARN-509 and a polymer selected from HPMCAS, poly (meth) acrylate copolymers and mixtures thereof. In one aspect, these formulations comprise solid dispersions of granules of abiraterone acetate and polymers selected from ARN-509 and HPMCAS, poly (meth) acrylate copolymers and mixtures thereof. |